TABLE 3.
Results per Regimen
| Second Line | LEN-DEX | BOR-DEX | CFZ-LEN-DEX | ELO-LEN-DEX | IX- LEN-DEX | DAR- LEN-DEX | DAR- BOR-DEX |
|---|---|---|---|---|---|---|---|
| Total costs, $ | 309,997 | 189,357 | 492,872 | 665,728 | 622,378 | 845,527 | 447,182 |
| Drug acquisition | 264,898 | 133,774 | 432,799 | 596,124 | 571,390 | 762,407 | 368,096 |
| Supportive care | 528 | 1,608 | 1,882 | 2,607 | 2,491 | 4,947 | 2,515 |
| Administration | − | 8,226 | 8,377 | 14,698 | − | 23,981 | 22,960 |
| Progression | 40,221 | 41,167 | 45,358 | 45,143 | 44,330 | 50,723 | 51,003 |
| Adverse event | 4,351 | 4,583 | 4,457 | 7,156 | 4,166 | 3,469 | 2,607 |
| Total QALYs | 2.59 | 2.74 | 3.45 | 3.41 | 3.27 | 5.44 | 5.29 |
| PFS | 1.41 | 1.50 | 1.91 | 1.89 | 1.81 | 3.13 | 3.05 |
| Progression | 1.17 | 1.24 | 1.54 | 1.52 | 1.46 | 2.31 | 2.24 |
| Total life-years | 3.53 | 3.73 | 4.71 | 4.66 | 4.46 | 7.38 | 7.11 |
| PFS | 1.73 | 1.83 | 2.34 | 2.31 | 2.21 | 3.82 | 3.67 |
| Progression | 1.80 | 1.91 | 2.37 | 2.34 | 2.25 | 3.55 | 3.44 |
| ICER vs. LEN-DEX | − | -792,583 | 211,458 | 430,009 | 454,684 | 187,728 | 50,704 |
| Third Line | LEN-DEX | BOR-DEX | CFZ-LEN-DEX | ELO-LEN-DEX | IX- LEN-DEX | PAN-BOR-DEX | DAR-LEN-DEX | DAR-BOR-DEX |
|---|---|---|---|---|---|---|---|---|
| Total costs, $ | 281,754 | 175,315 | 459,868 | 608,651 | 566,512 | 190,876 | 789,202 | 423,119 |
| Drug acquisition | 237,670 | 121,751 | 401,201 | 541,632 | 516,793 | 131,500 | 707,051 | 344,684 |
| Supportive care | 473 | 1,441 | 1,779 | 2,364 | 2,255 | 411 | 4,579 | 2,403 |
| Administration | 7,365 | 8,113 | 13,394 | − | 3,095 | 22,394 | 21,412 | |
| Progression | 39,261 | 40,175 | 44,318 | 44,105 | 43,298 | 46,744 | 51,708 | 52,014 |
| Adverse event | 4,351 | 4,583 | 4,457 | 7,156 | 4,166 | 9,127 | 3,469 | 2,607 |
| Total QALYs | 2.04 | 2.16 | 2.74 | 2.71 | 2.60 | 3.23 | 4.38 | 4.38 |
| PFS | 1.00 | 1.07 | 1.37 | 1.36 | 1.30 | 1.69 | 2.28 | 2.35 |
| Progression | 1.03 | 1.09 | 1.37 | 1.36 | 1.30 | 1.54 | 2.10 | 2.03 |
| Total life-years (OS) | 3.25 | 3.44 | 4.37 | 4.32 | 4.14 | 4.93 | 6.97 | 6.71 |
| PFS | 1.55 | 1.64 | 2.12 | 2.09 | 2.00 | 2.41 | 3.52 | 3.38 |
| Progression | 1.70 | 1.79 | 2.25 | 2.23 | 2.14 | 2.52 | 3.44 | 3.33 |
| ICER vs. LEN-DEX | − | -853,800 | 252,293 | 484,168 | 508,021 | Dominant | 216,360 | 60,359 |
BOR = bortezomib; CFZ = carfilzomib; DAR = daratumumab; DEX = dexamethasone; ELO = elotuzumab; ICER = incremental cost-effectiveness ratio; IX = ixazomib; LEN = lenalidomide; OS = overall survival; PAN = panobinostat; PFS = progression-free survival; QALY = quality-adjusted life-year.